Abstract

This core will provide Projects 1, 2 and 3 as well as the Antibody Core with necessary influenza virus reagents to conduct the proposed research. All three Projects as well as the Antibody Core will greatly benefit from this core's ability to produce a large panel of high quality recombinant influenza virus hemagglutinin and neuraminidase proteins as well as chimeric versions of these molecules. These proteins are functional, correctly folded and glycosylated and will be used in various assays by Project 1. 2 and 3 and as baiting agent by the Antibody Core. Furthermore, the core will produce custom made recombinant viruses that express chimeric hemagglutinin, neuraminidase and chimeric neuraminidase proteins in the influenza A and B virus background. Project 1 will use these viruses for analysis of monoclonal antibodies and for mimicking of preexisting immunity in animal models. Finally, the Reagent Core will supply Projects 1, 2 and 3 as well as the Antibody Core with high titer virus stocks, mouse adapted influenza virus challenge strains and purified virus preparations

Public Health Relevance

The Reagent Core will provide recombinant proteins and viruses that have been developed in the Palese laboratory and are not available from any other source. These reagents are essential for the research conducted in Projects 1. 2 and 3.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI109946-05
Application #
9648685
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Post, Diane
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
5
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029

  Publications

Coughlan, Lynda; Palese, Peter (2018) Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine. Cell Host Microbe 24:18-24
Krammer, Florian; Fouchier, Ron A M; Eichelberger, Maryna C et al. (2018) NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines? MBio 9:
Chen, Yao-Qing; Wohlbold, Teddy John; Zheng, Nai-Ying et al. (2018) Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies. Cell 173:417-429.e10
Henry, Carole; Palm, Anna-Karin E; Krammer, Florian et al. (2018) From Original Antigenic Sin to the Universal Influenza Virus Vaccine. Trends Immunol 39:70-79
Broecker, Felix; Liu, Sean T H; Sun, Weina et al. (2018) Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice. J Virol 92:
Nachbagauer, Raffael; Shore, David; Yang, Hua et al. (2018) Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge. J Virol 92:
Pardi, Norbert; Parkhouse, Kaela; Kirkpatrick, Ericka et al. (2018) Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat Commun 9:3361
Wang, Taia T; Bournazos, Stylianos; Ravetch, Jeffrey V (2018) Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. Curr Opin Immunol 53:124-129
Wilson, Patrick C; Cobey, Sarah (2018) Characterization of the immunologic repertoire: A quick start guide. Immunol Rev 284:5-8
Stamper, Christopher T; Wilson, Patrick C (2018) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Is Affinity Maturation a Self-Defeating Process for Eliciting Broad Protection? Cold Spring Harb Perspect Biol 10:

Showing the most recent 10 out of 80 publications